Comparison of Bone Microarchitecture Analysed by HRpQCT and pQCT in Pathologies With Bone Loss and/or Muscle Loss
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE SAINT ETIENNE · Aug 2, 2024
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how to better understand bone and muscle health in people who are at risk for conditions like osteoporosis, which causes bones to become weak and more likely to break. Researchers will use advanced imaging devices to look closely at the structure of bones and muscles in patients with various health issues, such as rheumatoid arthritis or neurological disorders. The goal is to gather important information that can help predict fracture risks more accurately than current methods, which often miss key details about bone structure.
To participate in the study, individuals must be between the ages of 65 and 74 and have certain conditions that put them at risk for osteoporosis, such as a history of brittle bone fractures or specific diseases like rheumatoid arthritis or chronic kidney disease. Participants will have their bone and muscle health assessed using special imaging techniques, and they will be contributing to research that could lead to better ways to manage bone health and reduce the chances of fractures in the future. It's important to note that individuals on certain medications or with specific medical histories may not be eligible for the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- For the patients:
- Women or men treated at the Saint-Etienne University Hospital and presenting an osteoporotic risk with one of the following associated pathologies:
- • Osteoporosis defined by: History of a documented brittle bone fracture
- • Bone fragility: Patient with indication for bone densitometry but no history of fracture
- * Inflammatory joint disease:
- • Rheumatoid arthritis
- • Spondyloarthritis
- • Chronic kidney disease
- * Endocrinopathies:
- • Primary hyperparathyroidism
- • Constitutional thinness
- • Anorexia nervosa
- • Obesity (BMI \>30)
- • Sarcopenia
- • Neuropathies - Parkinson's disease
- For the controls:
- • Acute episode of spinal or radiculalgia (less than one month old) with corticosteroid treatment of less than 1 month Signature of written consent
- Exclusion Criteria:
- • No sign written consent
- For the controls:
- * Medications inducing bone loss:
- • anti-aromasin or GnRH agonist for at least 6 months,
- • corticosteroids (dose ≥ 5 mg/d for 6 months)
- • anti-epileptic drugs: carbamazepine, phenobarbital, phenytoin, primidone, valproic acid for at least 6 months)
- • History of fracture due to bone fragility
- • Taking bone-targeting medication (biphosphonate, teriparatide, strontium ranelate)
About Centre Hospitalier Universitaire De Saint Etienne
The Centre Hospitalier Universitaire (CHU) de Saint-Étienne is a leading academic medical center in France, dedicated to advancing healthcare through innovative clinical research and high-quality patient care. With a robust infrastructure that supports a wide range of medical specialties, CHU de Saint-Étienne fosters collaboration between healthcare professionals, researchers, and academic institutions. The center is committed to conducting rigorous clinical trials that adhere to ethical standards and regulatory requirements, aiming to improve treatment outcomes and enhance the overall health of the community. Through its dedication to scientific excellence and patient-centered care, CHU de Saint-Étienne plays a pivotal role in the advancement of medical knowledge and the development of new therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint étienne, , France
Patients applied
Trial Officials
Hubert MAROTTE, PhD
Principal Investigator
CHU SAINT-ETIENNE
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported